Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
Stein Gunnar LarsenM A GoscinskiS DuelandS E SteigenE HofsliA TorgunrudM Lund-IversenV J DagenborgK FlatmarkH SorbyePublished in: British journal of cancer (2021)
PM-CRC with CRS-HIPEC patients has a surprisingly high proportion of mutBRAF (24.7%). Survival was similar comparing mutBRAF, mutKRAS and double wild-type cases, whereas a small subgroup with mutBRAF and MSI had better survival. Patients with mutBRAF tumours and limited PM should be considered for CRS-HIPEC.
Keyphrases
- end stage renal disease
- wild type
- ejection fraction
- newly diagnosed
- prognostic factors
- air pollution
- peritoneal dialysis
- particulate matter
- randomized controlled trial
- clinical trial
- patient reported outcomes
- atrial fibrillation
- quality improvement
- study protocol
- phase iii
- double blind
- metastatic renal cell carcinoma